DS
KERX

DRW Securities’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

DRW Securities’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-20,000
Closed -$259K – 262
2013
Q4 		$259K Buy
+20,000
New +$239K 0.01% 157

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

DRW Securities's KERX Position: Q1 2014 in Review

DRW Securities sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2014, closing a stake of 20,000 shares — an estimated $259K sold.

DRW Securities first reported a position in KERX in Q4 2013 and held it in 1 quarter. The position peaked at $259K in Q4 2013. 150 funds tracked by Wall St. Rank hold KERX as of Q1 2014.

  • DRW Securities reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2014 after selling out during the quarter.
  • DRW Securities sold 20,000 Keryx Biopharmaceuticals Inc shares in Q1 2014, an estimated $259K.
  • DRW Securities first reported a position in Keryx Biopharmaceuticals Inc in Q4 2013 and held it in 1 quarter.
  • DRW Securities's Keryx Biopharmaceuticals Inc position peaked at $259K in Q4 2013.
  • 150 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2014.

Based on DRW Securities's 13F filing for Q1 2014, filed 16 May 2014.